NICE has issued final draft guidance recommending Tryngolza (olezarsen) for adults in England and Wales with genetically confirmed familial chylomicronaemia syndrome, but only when response to diet ...
Boehringer Ingelheim has reported new phase 3 data showing its dual glucagon/GLP‑1 agonist survodutide achieved weight loss of up to 13.1% in adults with obesity and type 2 diabetes. The SYNCHRONIZE‑2 ...
Kither Biotech has started dosing patients in its phase 1b / 2a clinical study of KIT2014 in adults with moderate to severe ...
Quotient Sciences and Acesion Pharma have formed a new collaboration to apply AI‑enhanced formulation development within Quotient’s Translational Pharmaceutics platform. The partnership will support ...
Teva has received US FDA approval for DEGEVMA (denosumab‑adet), a biosimilar to Xgeva, marking a further step in its Pivot to Growth strategy. The product is authorised across all Xgeva indications, ...
Lexeo Therapeutics has signed an agreement to acquire Mantle Therapeutics and launched several new collaborations aimed at ...
AbbVie has received European Commission approval for Rinvoq to treat active polyarticular juvenile idiopathic arthritis in ...
It is a testament to investor success that over 100 exhibitors at CPHI 2026 have some form of PE ownership across the entire ...
Neuraxpharm and Minoryx have announced that the European Commission has granted marketing authorisation under exceptional ...
Ethiopia, Norway and the UK have pledged US$240 million to support CEPI’s five‑year plan to strengthen global readiness for epidemic and pandemic threats. Ethiopia will contin ...
AC Immune has reported positive week-100 results from part 1 of its phase 2 VacSyn trial evaluating ACI-7104 in early-stage ...
Grünenthal has entered a new partnership with DKSH to expand access to four established pain medicines across Asia-Pacific.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results